Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps.

ABSTRACT: Molecular Tumor Boards (MTBs) are pivotal in personalized cancer care. This systematic review and meta-analysis included 34 studies out of 576 articles (2020-January 2024) involving 12,176 patients across 26 major cancer entities. Of these, 20.8% (2,532 patients) received MTB-recommended therapies, with 178 outcome measures reported, achieving a median overall survival (OS) of 13.5 months, progression-free survival (PFS) of 4.5 months, and an objective response rate (ORR) of 5-57%. A pooled PFS2/PFS1 ratio ≥ 1.3 from 14 reports was observed in 38% (33-44%) of cases. Comparative data showed improved outcomes for MTB-treated patients, with hazard ratios of 0.46 (0.28-0.76, p < 0.001) for OS in 19 and 0.65 (0.52-0.80, p < 0.001) for PFS in 3 studies. These results highlight the benefits of MT

SUBMITTER: Gladstone BP 

PROVIDER: S-EPMC11965449 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature